Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

[News]

Regeneron Pharmaceuticals, Inc. today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

More... (http://www.news-medical.net/news/20110222/Regeneron-submits-VEGF-Trap-Eye-BLA-to-FDA-for-treatment-of-wet-AMD.aspx)